Antimicrobial peptides as therapeutic candidates against drug-resistant bacterial pathogens: Classification, mechanisms of action, resistance challenges, and translational prospects
Journal of Advances in Microbiology Research · 01.01.2026 · 7 (1) · 60-65
DOI: 10.22271/micro.2026.v7.i1a.352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Advances in Microbiology Research, online erschienen am 01.01.2026. Verfasst von Carlos Figueras und 2 weiteren Autor:innen.
Abstract (Originalsprache)
In the context of a global antimicrobial resistance crisis that is narrowing treatment options for life-threatening bacterial infections, Antimicrobial Peptides (AMPs) have attracted renewed interest as both therapeutic candidates and structural templates for drug development. AMPs are short (typically 10-50 amino acid), cationic, and often amphipathic peptides produced by virtually every living organism as part of innate immune defence. Their primary mechanism of action disruption of the bacterial cytoplasmic membrane through electrostatic interaction with anionic membrane components differs fundamentally from all classes of classical antibiotics and theoretically lowers the risk of cross-resistance. This review provides a comprehensive account of AMP biology, covering classification by source (amphibian, mammalian, plant, insect, marine, and bacteriocin classes), structural families (α-helical, β-sheet, loop, and extended peptides), and mechanism of action (barrel-stave, toroidal-pore, and carpet models of membrane disruption). The evidence for AMP activity against priority MDR pathogens methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, carbapenem-resistant Pseudomonas aeruginosa, and extended-spectrum β-lactamase-producing Enterobacteriaceae is reviewed against the backdrop of MIC comparisons, biofilm activity, and in vivo efficacy data. The mechanisms by which bacteria develop resistance to AMPs are examined including daptomycin resistance as a clinically validated precedent alongside strategies to overcome resistance through AMP engineering, d-amino acid incorporation, and hybrid AMP-antibiotic conjugates. The review surveys the clinical development pipeline, where AMP-based drugs including omiganan, pexiganan, and iseganan have reached clinical trials, with mixed results that illuminate the translational challenges. Future directions including synthetic biology approaches to AMP design, delivery systems for systemic AMP therapy, and immunomodulatory applications of host defence peptides are assessed.
Zitieren
APA
Figueras, C., Pereyra, V., & Rodríguez, M. (2026). Antimicrobial peptides as therapeutic candidates against drug-resistant bacterial pathogens: Classification, mechanisms of action, resistance challenges, and translational prospects. Journal of Advances in Microbiology Research, 7(1), 60-65. https://doi.org/10.22271/micro.2026.v7.i1a.352
Vancouver
Figueras C, Pereyra V, Rodríguez M. Antimicrobial peptides as therapeutic candidates against drug-resistant bacterial pathogens: Classification, mechanisms of action, resistance challenges, and translational prospects. Journal of Advances in Microbiology Research. 2026;7(1):60-65. doi:10.22271/micro.2026.v7.i1a.352
BibTeX
@article{Figueras2026,
author = {Figueras, Carlos and Pereyra, Valentina and Rodríguez, Marcos},
title = {Antimicrobial peptides as therapeutic candidates against drug-resistant bacterial pathogens: Classification, mechanisms of action, resistance challenges, and translational prospects},
journal = {Journal of Advances in Microbiology Research},
year = {2026},
volume = {7},
number = {1},
pages = {60--65},
doi = {10.22271/micro.2026.v7.i1a.352}
}
EUVIMED